Gastrointestinal stromal tumors (GISTs) are the most common malignant subepithelial
lesions (SELs) of the gastrointestinal tract. They originate from the interstitial cells of Cajal …

Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the
commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as …

1 ESGE recommends endoscopic ultrasonography (EUS) as the best tool to characterize
subepithelial lesion (SEL) features (size, location, originating layer, echogenicity, shape) …

Importance Three years of adjuvant imatinib mesylate therapy is associated with reduced
recurrence rates and improved overall survival in patients with high-risk primary …

Small submucosal tumors (SMT) without symptoms are frequently found by endoscopic and
radiological examinations. To find proper diagnostic measures and therapeutic indications …

Purpose Three years of adjuvant imatinib therapy are recommended for patients with GI
stromal tumor (GIST) with high-risk features, according to survival findings in the …

Importance Little is known about whether the duration of adjuvant imatinib influences the
prognostic significance of KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet …

Background Preoperative imatinib therapy of locally advanced GIST may facilitate resection
and decrease morbidity of the procedure. Methods We have pooled databases from 10 …

The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer
staging and treatment: 2015 | SpringerLink Skip to main content Advertisement …

Gastrointestinal stromal tumors are rare malignancies involving the intestinal tract. They are
now easily recognized using standard immunohistochemistry. Management in the past was …